SCHEMBL22065486

SCHEMBL22065486

Cc1c(CO)cccc1-c1cccc(OCCCN2CCCC2)c1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.56
CYP2C19 P33261 1/20 0.56
ALDH1A1 P00352 8/20 0.54
L3MBTL1 Q9Y468 4/20 0.54
HTT P42858 1/20 0.54
KDM4E B2RXH2 5/20 0.53
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
PKM P14618 1/20 0.53
HRH1 P35367 3/20 0.51
DRD2 P14416 1/20 0.51
DRD1 P21728 1/20 0.51
DRD4 P21917 1/20 0.51
DRD5 P21918 1/20 0.51
DRD3 P35462 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.50
KCNH2 Q12809 1/20 0.49
HRH3 Q9Y5N1 1/20 0.49
LMNA P02545 1/20 0.49
TP53 P04637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18761087 0.91 ALDH1A1 (0.58) CYP2D6CYP2C19ALDH1A1L3MBTL1HTT
SCHEMBL24445406 0.89 CYP2D6 (0.68) CYP2D6CYP2C19ALDH1A1L3MBTL1HTT
SCHEMBL19916129 0.88 CYP2D6 (0.66) CYP2D6CYP2C19ALDH1A1L3MBTL1HTT
SCHEMBL24445444 0.88 CYP2D6 (0.66) CYP2D6CYP2C19ALDH1A1L3MBTL1HTT
SCHEMBL24445402 0.87 CYP2D6 (0.58) CYP2D6CYP2C19ALDH1A1L3MBTL1HTT
SCHEMBL26194821 0.84 CYP2D6 (0.69) CYP2D6CYP2C19ALDH1A1L3MBTL1HTT
SCHEMBL20523339 0.84 CD274 (0.53) ALDH1A1KDM4EKMT2AMEN1HRH1
SCHEMBL30254987 0.84 CD274 (0.53) ALDH1A1KDM4EKMT2AMEN1HRH1
SCHEMBL20522859 0.84 CD274 (0.53) ALDH1A1KDM4EKMT2AMEN1HRH1
SCHEMBL19916130 0.83 CYP2D6 (0.59) CYP2D6CYP2C19ALDH1A1L3MBTL1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3601258-B1 SUBSTITUTED ISOQUIONLINE DERIVATIVES AS IMMUNOMUDULATORS BRISTOL MYERS SQUIBB CO (US) 2023-08-30 EP disclosed
US-11046675-B2 Substituted isoquionline derivatives as immunomudulators BRISTOL-MYERS SQUIBB COMPANY (US) 2021-06-29 US disclosed
US-20200181125-A1 SUBSTITUTED ISOQUIONLINE DERIVATIVES AS IMMUNOMUDULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2020-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200181125-A1 SUBSTITUTED ISOQUIONLINE DERIVATIVES AS IMMUNOMUDULATORS CD74, HLA-DRB1, ICOS CYP2D6 990/4885CYP2C19 3133/4885ALDH1A1 1196/4885
US-11046675-B2 Substituted isoquionline derivatives as immunomudulators CD74, HLA-DRB1, ICOS CYP2D6 990/4885CYP2C19 3133/4885ALDH1A1 1196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.